The ability of an artificial neural network to analyse protein sequence data could be exploited to help inform the development of more targeted pharmaceutical proteins and other drugs
A novel machine-learning ‘toolbox’ that can read and analyse the sequences of proteins has been described today in the open-access journal eLife.
The study demonstrates that, when trained to read sequence data, artificial neural networks called Restricted Boltzmann Machines (RBM) can provide a wealth of information on protein structure, function and evolutionary features. It is believed to be the first method that can extract this level of detail from sequence data alone.
Proteins are formed of sequences of molecules called amino acids, which determine a given protein’s structural and functional properties. But understanding which parts of the sequences are responsible for which properties is challenging. “Answering this question could have significant implications for pharmaceutical development,” explains co-author Jérôme Tubiana, former PhD student in the Physics Laboratory at l’École Normale Supérieure (ENS), Paris, France. “For example, it could help with the design of new proteins that have desired functions, or with predicting the future sequence evolution of proteins in living organisms, such as pathogens, and identifying appropriate drug targets.”
To explore this question, Tubiana and his collaborators applied RBM to 20 protein ‘families’ – a group of proteins that share a common evolutionary origin. The researchers presented detailed results for four protein families, including two short protein domains called Kunitz and WW, one long chaperone protein called Hsp70, and synthetic lattice proteins for benchmarking.
They discovered that, after learning, the connections between the artificial neurons
in the RBM are interpretable and relate to the protein’s structure, function (such as
activity) or phylogeny – the evolutionary relationships between protein sequences. Additionally, the team found that they could use RBM to design new protein sequences by composing and turning up or down the different artificial neural units at will.
“Our RBM model shows how machine-learning techniques can solve complex data recognition and draw conclusions from data in an interpretable way,” says co-author Simona Cocco, CNRS Director of Research at the ENS Physics Laboratory. “This runs counter to the more complex, black-box models that are traditionally used in data science, as statistical analyses provided by these tools are largely uninterpretable. The interpretability of our method is a major benefit to scientists – it bears the promise of allowing them to generate proteins with desired functions in a controlled way.”
“It will now be interesting to apply our model to proteins in pathogens,” adds senior author Rémi Monasson, also CNRS Director of Research at the ENS Physics Laboratory, and Deputy Director of the Henri Poincaré Institute (CNRS/Sorbonne University), France. “Pathogens, particularly viruses, can often escape drugs through mutations that make treatments ineffective. Our method could be used to predict the mutational escape paths that are accessible to the functional protein from its current sequence, and help identify which combination of protein sites should be targeted by drugs to block all paths.”
###
Reference
The paper ‘Learning protein constitutive motifs from sequence data’ can be freely accessed online at https:/
Authors Simona Cocco and Rémi Monasson are affiliated with the ENS Physics Laboratory (CNRS/ENS Paris/Sorbonne Université/Université Paris Diderot).
Media contact
Emily Packer, Senior Press Officer
eLife
[email protected]
01223 855373
About eLife
eLife aims to help scientists accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours in science. We publish important research in all areas of the life and biomedical sciences, including Computational and Systems Biology and Physics of Living Systems, which is selected and evaluated by working scientists and made freely available online without delay. eLife also invests in innovation through open-source tool development to accelerate research communication and discovery. Our work is guided by the communities we serve. eLife is supported by the Howard Hughes Medical Institute, the Max Planck Society, the Wellcome Trust and the Knut and Alice Wallenberg Foundation. Learn more at https:/
To read the latest Computational and Systems Biology research published in eLife, visit https:/
And for the latest Physics of Living Systems research, see https:/
Media Contact
Emily Packer
[email protected]
Related Journal Article
https:/
http://dx.